Home › Funds › Frazier Life Sciences Management, L.P. › CLDX
Frazier Life Sciences Management, L.P. position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Frazier Life Sciences Management, L.P. reported holding 900,080 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$29.2M, representing 0.74% of its reported portfolio and ranking #25 among its reported holdings. Frazier Life Sciences Management, L.P. first reported this position in Q3 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Frazier Life Sciences Management, L.P.'s CLDX position evolved
Frazier Life Sciences Management, L.P. first disclosed a stake in CLDX in Q3 2026 at 900,080 shares (US$29.2M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 900.08K | $29.17M | New |
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 35 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), BAKER BROS. ADVISORS LP (US$83.1M), Deep Track Capital, LP (US$68.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.07M sh · $164.19M · Q3 2026
- BAKER BROS. ADVISORS LP 2.56M sh · $83.13M · Q3 2026
- Deep Track Capital, LP 2.13M sh · $68.89M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M sh · $61.46M · Q3 2026
- Eversept Partners, LP 1.17M sh · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M sh · $37.61M · Q3 2026
- Elmind Capital, LP 1.11M sh · $35.98M · Q3 2026
- Commodore Capital LP 1.00M sh · $32.41M · Q3 2026
- Novo Holdings A/S 950.00K sh · $30.79M · Q3 2026
- ADAR1 Capital Management, LLC 799.30K sh · $25.91M · Q3 2026
- Trails Edge Capital Partners, LP 765.00K sh · $24.79M · Q3 2026
More on Frazier Life Sciences Management, L.P.
FAQ
How long has Frazier Life Sciences Management, L.P. held CLDX?
Frazier Life Sciences Management, L.P. has disclosed CLDX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Frazier Life Sciences Management, L.P.'s current position in CLDX?
As of Q3 2026, Frazier Life Sciences Management, L.P. holds 900.08K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $29.17M, representing 0.74% of its reported portfolio and ranking #25.
Has Frazier Life Sciences Management, L.P. been buying or selling CLDX?
In the latest 13F filing (Q3 2026), Frazier Life Sciences Management, L.P. newly opened its position in CLDX.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, BAKER BROS. ADVISORS LP, Deep Track Capital, LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.